An increased risk of breast cancer in night workers may in part be mediated by the melatonin pathway

 

Previous observational studies, prompted by the theory that melatonin suppression increases cancer risk, suggest a positive association between night work and breast cancer risk. Melatonin, a hormone with potential oncostatic activity, is produced almost exclusively during the night and is acutely suppressed by exposure to light at night such as in night workers. However, the relationship between circulating melatonin levels and breast cancer risk remains unclear. 

To further evaluate the melatonin hypothesis, we prospectively examined associations between history of night work in nurses and breast cancer risk in the Nurses' Health Study II (NHSII). We also examined associations between urinary melatonin levels and subsequent breast cancer risk.Participants included 115,022 predominantly premenopausal women who were free of cancer at baseline in 1989. Of these, 1,352 were diagnosed with invasive breast cancer during 12 years of follow-up. At baseline and at 2 to 4 year intervals, we assessed the number of years the nurses worked rotating night shifts defined as at least three nights per month. As part of a case-control study nested within the NHSII cohort, we evaluated morning levels of urinary 6-sulfatoxy (aMT6s) melatonin in 190 women who developed breast cancer during 4 years of follow-up and in 376 matched controls. Samples were collected between 1996 and 1998. We used Cox proportional hazards models to evaluate associations between duration of night shift work and breast cancer risk, adjusting for several breast cancer risk factors. We used logistic regression to evaluate associations of urinary melatonin and breast cancer risk. Women reporting more than 20 years of rotating night shift work experienced an elevated age-adjusted relative risk of breast cancer compared to women who did not engage in rotating night shift work (RR, 1.88; 95% CI, 1.12 to 3.15). After further adjustment for several important breast cancer risk factors, the association was virtually unchanged (RR, 1.79; 95% CI, 1.06-3.01). Assessed at baseline, having worked rotating night shifts for more than 20 years was also significantly associated with breast cancer risk (multivariate RR, 2.79, 95% CI, 1.38-5.66), compared to women without any night work. In contrast, there was no increase in risk associated with an intermediate number of years of rotating night work (RR, 1.0, 0.98, and 0.91 for 0, 1-9, and 10-19 years of night work, respectively). Controlling for matching factors, the RR of invasive breast cancer associated with the lowest compared with the highest quartile of urinary aMT6s was 1.70 (95% CI, 1.04-2.78). Associations were similar after further adjustment for breast cancer risk factors (RR, 1.70; 95% CI, 1.02-2.82) and plasma sex hormone levels and after the exclusion of night workers (RR, 1.67; 95% CI, 0.97-2.90). 
In conclusion, women who worked 20 or more years of rotating night shifts had an increased risk of breast cancer. Moreover, lower melatonin levels were associated with a higher breast cancer risk in this cohort of women. Our findings suggest that an increased risk of breast cancer in night workers may in part be mediated by the melatonin pathway.

 

Bibliographical references:

 

Eva Schernhammer

Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts